LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-21. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
== Extra reading == Habibullah, Mahmoud M; Mohan, Syam; Syed, Nabeel Kashan; Makeen, Hafiz A; Jamal, Qazi Mohammad Sajid; Alothaid, Hani; Bantun, Farkad; Alhazmi, Alaa; Hakamy, Ali; Kaabi, Yahia A; Samlan, Ghalia; Lohani, Mohtashim; Thangavel, Neelaveni; Al-Kasim, Mohamed Ahmed (June 2022). "Human Growth Hormone Fragment 176–191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells". Drug Design, Development and Therapy. 16: 1963–1974. doi:10.2147/DDDT.S367586. PMC 9249349. PMID 35783198.
Daisho (Dso) is an antimicrobial peptide gene family of the fruit fly Drosophila melanogaster. Two Daisho genes (Dso1, Dso2) are encoded in tandem in the fruit fly genome, one shorter than the other. This pair of genes with different length was named "Daisho" in reference to Daisho Japanese swords, which come in pairs with one shorter than the other. The Daisho genes are regulated by Drosophila Toll-like receptor signalling. Daisho peptides protect flies against filamentous fungi, particularly Fusarium and also Aspergillus. Daisho peptides are part of the Drosophila antifungal effector peptide response, which includes the gene families Bomanin, Drosomycin, Metchnikowin, and Baramicin.
==== Structured breast prosthesis ==== The fourth category of prosthetic-breast technology is the structured breast-prosthesis, which was approved for breast surgery by the Food and Drug Administration in the U.S. and by Health Canada in Canada in 2014. As a medical device, the structured prosthetic-breast incorporates the technologies of saline-solution and of silicone-gel to achieve anatomical function and aesthetic symmetry. Technologically, the internal structure of the breast prosthesis is composed of three, nested shells (made of silicone rubber) that support the upper half of the breast hemisphere; the two spaces between the three nested shells is filled with saline solution. To implant a structured breast prosthesis, the plastic surgeon emplaces the folded, empty prosthetic breast into the implant-socket, then fills the prosthetic breast with saline solution, and afterwards sutures shut the insertion incision.
Sources: en.wikipedia.org
=== Debridement === Debridement is defined as removal of devitalized or dead tissue, particularly necrotic tissue, eschar, or slough. Debridement is a critical aspect of wound care because devitalized tissue, particularly necrotic tissue, serves as nutrients for bacteria thereby promoting infection. Additionally, devitalized tissue creates a physical barrier over a wound which limits the effectiveness of any applied topical compounds and prevents re-epithelialization. Lastly, devitalized tissue, especially eschar, prevents accurate assessment of underlying tissue, making appropriate assessment of a wound impossible without adequate debridement. Debridement can be achieved in several ways:
The origins of Cannabis are linked to a Scythian word. The ancient Greeks may have learned of the use of cannabis, which they called κάνναβις, by observing Scythian funerals, during which cannabis was consumed. In Akkadian, cannabis was known as qunubu (𐎯𐎫𐎠𐎭𐏂). The word was adopted in to the Hebrew as qaneh bosem (קָנֶה בֹּשׂם). The Latin term cannabis derived from Greek evolved into Proto-Germanic *xan(a)paz, yielding various Germanic forms (Old Norse hampr, Old English hænep, Old Saxon hanup, Old High German hanaf) and ultimately modern British English "hemp."
== Causes == The American Cancer Society noted that several factors contributed to escalating nationwide drug shortages, which included decreased or restricted drug manufacturing capacity, increased drug demands coupled with corresponding shortages in supplies, and lower profit margins for several generic drugs decreasing corporate desires towards creating surpluses. The organization also noted that the Food and Drug Administration's means to prevent drug shortages were fundamentally centered around contact with the drug manufacturers involved, giving early warnings that requested them to increase production instead of directly pushing for specific drug quotas. The ASHP reported that one of the main causes of continuous severe shortages was due to "extreme price competition" between generic drug manufacturers. Challenges to quick-enough production of high-quality medications coupled with possible supply chain disruptions pushed many of these companies to shift their manufacturing to producing drugs with higher profit margins, with some completely stopping production of less lucrative drugs. The organization also pointed out the role that difficult and multi-year federal regulatory approval processes for new manufacturers played in lowering the number of new drug manufacturers and resulting supply decreases. Generic drug user fees noted in section 506C(g) of the Federal Food Drug and Cosmetics Act further made it difficult for companies to keep their businesses profitable. U.S.
== Prognosis == Prognosis depends on the condition itself. Some conditions such as MS depend on the subtype of the disease and various attributes of the patient such as age, sex, initial symptoms, and the degree of disability the patient experiences. Life expectancy in MS patients is 5 to 10 years lower than unaffected people. MS is an inflammatory demyelinating disease of the central nervous system (CNS) that develops in genetically susceptible individuals after exposure to unknown environmental trigger(s). The bases for MS are unknown but are strongly suspected to involve immune reactions against autoantigens, particularly myelin proteins. The most accepted hypothesis is that dialogue between T-cell receptors and myelin antigens leads to an immune attack on the myelin-oligodendrocyte complex. These interactions between active T cells and myelin antigens provoke a massive destructive inflammatory response and promote continuing proliferation of T and B cells and macrophage activation, which sustains secretion of inflammatory mediators. Other conditions such as central pontine myelinolysis have about a third of patients recover and the other two-thirds experience varying degrees of disability. In some cases, such as transverse myelitis, the patient can begin recovery as early as 2 to 12 weeks after the onset of the condition.
Sources: en.wikipedia.org
=== Prevention of suicide === Lithium has been shown to reduce the risk of suicide in individuals with bipolar disorder or major depression to close to the same level as that of the general population. It is thought to exert this effect by treating the underlying mood disorder and through a reduction in impulsivity and aggressiveness. Lithium is proven to reduce the risk of suicide in mood disorders by 87% in randomized double-blind placebo-controlled trials. Some meta-analyses have not found a statistically significant association between lithium and a reduction in suicide, however these meta-analyses are disputed. Some evidence suggests lithium is effective in significantly reducing the risk of self-harm and unintentional injury for bipolar disorder in comparison to no treatment and to antipsychotics or valproate. In addition, lithium decreases all-cause mortality in people with bipolar disorder. The increased presence of trace amounts of lithium in drinking water is correlated with lower overall suicide rates, especially among men. Lithium in drinking water is also associated with lower rates of homicide, rape, drug arrests, and other crimes.
Macimorelin (INN) – or Macrilen (trade name) – is a drug that was developed by Aeterna Zentaris for use in the diagnosis of adult growth hormone deficiency. Macimorelin acetate, the salt formulation, is a synthetic growth hormone secretagogue receptor agonist. It is a growth hormone secretagogue receptor (ghrelin receptor) agonist, causing release of growth hormone from the pituitary gland. Macimorelin acetate is described chemically as D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-acetate. Macimorelin (Macrilen) was invented and first synthesized at University of Montpellier, Centre National de la Recherche Scientitifique (CNRS), France. This transpired from a long-lasting research collaboration with Aeterna Zentaris. Aeterna Zentaris later in-licensed macimorelin as a development candidate from the CNRS and proceeded with the pre-clinical and clinical development of the compound. As of January 2014, it was in Phase III clinical trials. The phase III trial for growth hormone deficiency is expected to be complete in December 2016. As of December 2017, it was FDA-approved as a method to diagnose growth hormone deficiency. Traditionally, growth hormone deficiency was diagnosed via means of insulin tolerance test (IST) or glucagon stimulation test (GST). These two means are done parenterally, whereas Macrilen boasts an oral formulation for ease of administration for patients and providers. In November 2018 Novo Nordisk would acquire the rights to Macrilen, at a cost of $145 million.
Though the band's previous taste for improvisation was now tightly reined in, one instrumental ("The Sheltering Sky") emerged from group rehearsals, while the noisy, half-spoken/half-shouted "Indiscipline" was a part-written, part-improvised piece created in order to give Bruford a chance to escape from the strict rhythmic demands of the rest of the album. Released in September 1981, Discipline reached No. 41 in the UK and No. 45 in the US. In June 1982, King Crimson followed Discipline with Beat, the first King Crimson album recorded with the same line-up as the album preceding it. Beat was also the group's only album where Fripp had no involvement in the original mixing, with Davies and Belew undertaking production duties. The album was themed around the lives and works of Beat Generation writers, reflected in song titles such as "Neal and Jack and Me" (inspired by Neal Cassady and Jack Kerouac), "Heartbeat" (inspired by Carolyn Cassady's memoir Heart Beat: My Life with Jack and Neal), "The Howler" (inspired by Allen Ginsberg's "Howl") and "Waiting Man" (inspired by William S. Burroughs). The album contained themes of life on the road, existential angst and romanticism. While Beat was more pop-influenced than Discipline, it also featured the improvised "Requiem", which featured Frippertronics, a guitar technique invented by Eno and Fripp using a tape loop system. The recording of Beat was marred by tension within the band, with Belew suffering stress over his duties as frontman, lead singer, and principal songwriter.
==== Media, social, internal and foreign affairs ==== Defense, National Security and Emergency Committee Diplomatic and Consular Affairs Committee Public Freedoms and Human Rights Committee Media Committee Social Affairs and Labor Committee Youth and Sports Committee Family and Women Committee Endowments, Religious Affairs and Fatwa Committee
=== Other antibiotics === Alternatives to fosfomycin include nitrofurantoin, pivmecillinam, and co-amoxiclav in oral treatment of urinary-tract infections associated with extended-spectrum beta-lactamase. In a separate study, CRE were treated with colistin, amikacin, and tigecycline, and emphasizes the importance of using gentamicin in patients undergoing chemotherapy or stem-cell therapy procedures. While colistin had shown promising activity against carbapenemase-producing isolates, more recent data suggest a resistance to it is already emerging and it will soon become ineffective. Using another antibiotic concomitantly with carbapenem can help prevent the development of carbapenem resistance. One specific study showed a higher rate of carbapenem resistance when using meropenem alone compared with combination therapy with moxifloxacin. In addition, several drugs were tested to gauge their effectiveness against CRE infections. In vitro studies have shown that rifampin has synergistic activity against carbapenem-resistant E. coli and K. pneumoniae. However, more data are needed to determine if rifampin is effective in a clinical setting. Several new agents are in development. The main areas where scientists are focusing is new β-lactamase inhibitors with activity against carbapenemases. Some of these include MK-7655, NXL104, and 6-alkylidenepenam sulfones. The exact way they affect the carbapenemases is unknown. Another experimental agent with activity against CRE is eravacycline.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.